Movement Disorders

The chief scientific officer of the Parkinson’s Foundation discussed strategies to close the gap between household income and telehealth use.

Gocovri is now the only therapy to be approved in the US to treat both off episodes and dyskinesia in patients with Parkinson disease.

Neurocrine Biosciences and Voyager Therapeutics have terminated the Parkinson disease portion of their partnership, ending development for VY-AADC, also known as NBIb-1817.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine explained the various factors that make Parkinson so difficult to manage.

Here's what is coming soon to NeurologyLive.

The study also found that patients with PD that used telehealth for mental health services were less likely to prefer telehealth over in-office visits.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

If approved, adaptive DBS could be added to Medtronic’s Percept device, which was approved in June 2020.

Rafael Carbunaru, PhD, MSc, vice president, research and development, Neuromodulation, Boston Scientific, discussed the system’s recent FDA approval.

Here's what is coming soon to NeurologyLive.

Patients with SCD and schizophrenia specifically had increased risk of developing Parkinson disease later in life.

The chief medical officer at SanBio discussed how the investigational agent SB623 can fill the void of disease-modifying therapies for TBI.

Olfactory impairment is indicative of rapid eye movement sleep behavior disorder, a prodromal symptom of Parkinson disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 22, 2021.

This fourth-generation system since 2012 is indicated as adjunctive therapy for stimulation of the subthalamic nucleus and internal globus pallidus to treat Parkinson symptoms.

The harmful association seen with antidepressants is complicated by their need in patients with HD and mood disturbance. There were also associations identified with alcohol and substance use.

The associate professor at Hokkaido University and investigator of STEMTRA also discussed other efforts in stroke, Alzheimer disease, and Parkinson disease.

Further associations with lowered risk of Parkinson were observed with BMI and coffee intake.

Here's what is coming soon to NeurologyLive.

The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.

Men were observed to derive benefit from a Greek Mediterranean diet and women were found to generally adhere more closely to diet interventions than men.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

The executive director of the Norman Fixel Institute for Neurological Diseases gave his call-to-action on how to change the approval system for neurologic devices for rare diseases.

Research led by movement disorders specialist Un Jung Kang, MD, searches for clues to help diagnose and treat Parkinson’s disease in its earliest stages, well before symptom onset.

Here's what is coming soon to NeurologyLive.

The chief medical officer of Cerevel Therapeutics detailed the TEMPO trials, a trio of studies that will examine tavapadon in patients with early and late-stage Parkinson disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

Andrea Quattrone, MD, discusses how his team worked to create a simpler biomarker after developing MRPI 2.0.

The chief medical officer of CND Life Sciences and medical director of Honor Health Neurology spoke to the role synuclein has played in advancing PD diagnosis.